Development and Evaluation of Polymethacrylate-Based Ophthalmic Nanofiber Inserts Containing Dual Drug-Loaded...

Area of Science:

• Ophthalmology
• Materials Science
• Nanotechnology

Background:

• Glaucoma is a group of chronic ocular disorders characterized by elevated intraocular pressure (IOP).
• Current treatments, often eye drops, face challenges with adherence and fluctuating drug levels.
• Developing advanced drug delivery systems is crucial for improved glaucoma management.

Purpose of the Study:

• To develop and evaluate a nanofiber insert for sustained delivery of Timolol (TIM) and Dorzolamide (DOR).
• To assess the safety and efficacy of the novel drug delivery system for glaucoma management.

Main Methods:

• Electrospinning of Eudragite RL100 (EUD) polymer to create drug-loaded nanofibers.
• Characterization of morphology, drug-polymer interactions, and physicochemical properties.
• In vitro drug release, pharmacokinetic analysis, and in vivo ocular irritation/compatibility studies in rabbits.

Main Results:

• Uniform nanofibers (< 465 nm diameter) with sustained release of DOR/TIM over 80 hours were achieved.
• High cell viability and no ocular irritation in rabbit models confirmed safety.
• Pharmacokinetic analysis showed significant Area Under the Curve (AUC0-72) and Mean Residence Times (MRTs) for both drugs.

Conclusions:

• The dual drug-loaded nanofiber system demonstrates potential as a preservative-free alternative to eye drops.
• This innovative system can effectively reduce fluctuations in drug concentration and decrease dosing frequency.
• Further research may validate this nanofiber insert for clinical application in glaucoma therapy.